Using cMab U36 labeled with 211Astatine showed reliable results in treating rats with HNSCC; on the other hand, combining this radioimmunotherapy with cetuximab revealed better results in controlling carcinoma and drew attention to interactions between CD44v6 and epidermal growth factor receptor (EGFR).170. Here, EGFR is linked to head and neck squamous cell carcinoma.